Syndicate content

Archive - Nov 24, 2015

Therapeutic Solutions International (TSI) Announces Licensing of Patents to Subsidiary OmniBiome; Focus Is On Pregnancy Complications & Materno-Fetal Immunology; Iryna Dzieciuch Named OmniBiome CEO

Therapeutics Solutions International (TSI), Inc. (OTC PINK: TSOI) announced on November 18, 2015 that the company has licensed three patents to OmniBiome, Inc., a wholly-owned subsidiary of TSI focused on fetal-maternal health, with the company's goal to assist women in the treatment or prevention of pre-term birth and pregnancy complications. The following patent applications were recently filed by TSI, the subject of recent press releases, and are now licensed to OmniBiome: Application No. 62/213260 titled "Preventative Methods and Therapeutic or Pharmaceutical Compositions for the Treatment or Prevention of Pregnancy Complications" covers utility of vaccines and various agents to alter pathological conditions in which the maternal immune system induces a process of inflammation that culminates in placental alterations leading to either fetal loss or preterm labor. Press Release of (9/8/2015); Application No. 62/219020 "Diagnostic Methods For The Assessment Of Pregnancy Complications" a cytokine-based diagnostic kit aimed at stratifying risk of pre-term labor and other pregnancy-associated complications. Press Release of 9/21/2015; Application No. 62/232722 "A Medical Device for Reducing the Risk Of Preterm-Labor And Preterm-Birth" covering various medical devices aimed at immune modulating the cervical microenvironment in order to prevent preterm labor. Press Release of 9/29/2015. "We are very excited to announce today that we have licensed intellectual property to our wholly-owned subsidiary OmniBiome. In addition, Iryna Dzieciuch (photo), M.S. has accepted the appointment as CEO of OmniBiome with the vision and motivation to dominate the space of maternal-fetal immunology by leveraging the patents which are the subject of this licensing agreement," said Timothy Dixon, President and CEO of TSI.

Exosome Diagnostics Launches “Academic Bench to Clinical Diagnostics” Assay Commercialization Program; Approach Lauded by Renowned Harvard/MGH Researcher Xandra Breakefield

Exosome Diagnostics, the developer of the leading liquid biopsy platform that enables non-invasive diagnosis of disease states, aiming to obviate the need for tissue biopsies, has announced its “Academic Bench to Clinical Diagnostics” (A to D) Assay Commercialization Program. The “A to D” program will provide academic and clinical researchers a means for bringing their biomarkers and assays to the clinical laboratory, while simultaneously utilizing the experience of the Exosome Diagnostics team to navigate the regulatory approval, reimbursement, commercialization, and business development processes. Researchers are developing novel biomarkers and assays with the company’s patented exosome isolation and RNA extraction technology using the exoRNeasy research kits marketed by QIAGEN. The exoRNeasy kit enables a convenient, robust, and high-yield isolation of exosomal RNA from blood. Under this “A to D” program researchers will now be able to bring their assays to Exosome Diagnostics for further validation by leveraging the company’s expertise in exosome isolation and analysis and development on the company’s proprietary clinical testing platforms, ExoLution™ for RNA-based biomarkers and assays, and ExoLutionPlus™ for the addition of cell-free DNA (cfDNA) for increased sensitivity of rare mutations when necessary. The ExoLution platforms have been developed and will be manufactured under cGMP to enable the exosome biomarkers to be extracted for clinical use, and are only available directly through Exosome Diagnostics. Simultaneously, the Regulatory Affairs team at Exosome Diagnostics will work with the appropriate regulatory agencies worldwide to ensure the fastest route for diagnostics approval.

Indestructible Micro-Animal Found to Have Almost 18% Foreign DNA in Genome; Only Animal Known to Survive Extreme Environment of Outer Space; Extensive Horizontal Gene Transfer Plays Key Role

Researchers from the University of North Carolina (UNC) at Chapel Hill have sequenced the genome of the nearly indestructible tardigrade, the only animal known to survive the extreme environment of outer space, and found something they never expected: that tardigrades get a huge portion of their genome - nearly one-sixth or 17.5 percent - from foreign DNA. "We had no idea that an animal genome could be composed of so much foreign DNA," said co-author Bob Goldstein, Ph.D., faculty in the biology department in UNC's College of Arts and Sciences. "We knew many animals acquire foreign genes, but we had no idea that it happens to this degree." Tardigrades are water-dwelling, eight-legged, segmented micro-animals. The new work, published online on November 23, 2015 in PNAS, not only raises the question of whether there is a connection between foreign DNA and the ability to survive extreme environments, but further stretches conventional views of how DNA is inherited. The artivcle is titled “Evidence for Extensive Horizontal Gene Transfer from the Draft Genome of a Tardigrade.” First author Thomas Boothby, Ph.D., Dr. Goldstein, and collaborators revealed that tardigrades acquire about 6,000 foreign genes primarily from bacteria, but also from plants, fungi, and Archaea, through a process called horizontal gene transfer - the swapping of genetic material between species as opposed to inheriting DNA exclusively from parents. Previously, another microscopic animal called the rotifer was the record-holder for having the most foreign DNA, but it has only about half as much as the tardigrade. For comparison, most animals have less than one percent of their genome from foreign DNA.

Pigeons Almost Equal to Radiologists in Ability to Detect Malignant Human Breast Pathology from Images

Pigeons may be able to distinguish between benign and malignant breast histology and radiology, according to an animal behavioral study published on November 18, 2015 in the open-access journal PLOS ONE by Richard Levenson, M.D., from the University of California-Davis Medical Center, Edward Wasserman, Ph.D., from the University of Iowa, and colleagues. The article is titled “Pigeons (Columba livia) As Trainable Observers of Pathology and Radiology Breast Cancer Images.” Pathologists and radiologists spend years acquiring and refining their medically essential visual skills. To better understand these skills, scientists trained several cohorts of pigeons, which share many visual system properties with humans, to view and identify benign and malignant histopathology and radiology images in a series of experiments. After training with differential food reinforcement and controlling for various parameters, including image magnification, compression, and color and brightness, the birds quickly learned to distinguish benign from malignant human breast histopathology. Additionally, the pigeons were able to generalize what they had learned to novel image sets. The birds' histological accuracy, similar to humans, was modestly affected by the presence or absence of color, as well as by degrees of image compression, but the authors suggest these impacts could be ameliorated with further training. In radiology, the birds were similarly capable of detecting cancer-relevant microcalcifications on mammogram images. However, when given a different task--namely, classification of suspicious mammographic densities--the pigeons were only able to memorize the images and were not able to generalize to novel images.